In no event shall TI or its suppliers be liable for any indirect, incidental or consequential damages, loss of profits, loss of use or data, or interruption of business, whether the alleged damages are labeled in tort, contract or indemnity.
Some states or jurisdictions do not allow the exclusion or limitation of incidental or consequential damages, so the above limitation may not apply. This Agreement will immediately terminate if you fail to comply with its terms.
Upon termination of this Agreement, you agree to return or destroy the original package and all whole or partial copies of the Program in your possession and so certify in writing to TI. The export and re-export of United States original software and documentation is subject to the Export Administration Act of as amended.
Compliance with such regulations is your responsibility. You agree that you do not intend to nor will you, directly or indirectly, export, re-export or transmit the Program or technical data to any country to which such export, re-export or transmission is restricted by any applicable United States regulation or statute, without the proper written consent or license, if required, of the Bureau of Export Administration of the United States Department of Commerce, or such other governmental entity as may have jurisdiction over such export, re-export or transmission.
If the Program is provided to the U. Government pursuant to a solicitation issued on or after December 1, , the Program is provided with the commercial license rights and restrictions described elsewhere herein. Localization: German 2. Localization: Spanish 2.
Localization: French 2. Localization: Italian 2. Localization: United Kingdom 2. Thirty-day revascularization was reduced in the stent group and did not differ significantly from that of the CABG-with-arterial-graft group. Otherwise, the results were similar to those of the total adjusted population. This study is the first Korean multicenter registry that compares the long-term clinical outcomes of two currently used coronary revascularization strategies.
Short- and long-term mortality rates did not differ significantly between the PCI and CABG groups after up to three years of follow-up. Short- and long-term mortality rates did not differ significantly between the PCI and CABG groups for diabetic or non-diabetic patients, although there was a trend in the PCI group towards an increased three-year mortality rate among diabetics.
In a separate analysis of arterial graft vs. Our current practice of selecting the treatment modality for patients with MVCAD is based on the results of many prior randomized trials 1 - 7. The BARI study is representative of the pre-stent era. The seven-year survival rate was In the Emory Angioplasty versus Surgery Trial EAST , treated diabetics showed similar mortality rates to non-treated diabetics until the three-year follow-up.
However, the curves began to diverge after five years, and by eight years, mortality rates were better after surgery, although the differences were not statistically significant The results of the Coronary Angioplasty versus Bypass Revascularization Investigation CABRI trial also indicated that there was no significant difference in four-year mortality rates between patients randomized to either PCI or CABG strategies, in either diabetic or non-diabetic patients, although diabetes was a significant risk factor for mortality Since the completion of these early major trials, significant technological advances have been made in the field of coronary revascularization, in both PCI and CABG.
Stent implantation is associated with greater clinical success, and a significantly lower long-term revascularization rate 9 , Recent PCI vs. Repeat revascularization rates seemed to improve in the stent group compared with the rates for the balloon groups of previous studies.
However, rates of revascularization were still significantly higher than those of the CABG group, particularly for treated diabetics. The prevalence of diabetes has been increasing explosively in Korea, as in other eastern societies This is also true for mortality from coronary artery disease, which parallels the prevalence of diabetes Treatment for coronary artery disease in diabetic patients is still not satisfactory in terms of long-term mortality and morbidity.
Despite many multicenter trials, the most appropriate selection of a revascularization strategy remains to be established, particularly in diabetic patients with multivessel disease.
In Korea, Sim et al. This Korean registry study will increase our understanding of the current situation and the outcomes associated with revascularization procedures in this region of the world.
KORR showed similar short- and long-term mortality rates for the two therapeutic modalities. These results are consistent with most previous comparative studies on PCI vs. Similar survival rates were observed for both diabetic and non-diabetic patients. In our data, however, the day mortality rate of patients with ACS was less than 2. When considering the relative merits of the two revascularization techniques in the management of MVCAD in the post-stent era, the two techniques seem equivalent in terms of survival.
Treated diabetes was a risk factor for long-term mortality only in the PCI group, but the relative advantages and disadvantages of CABG compared with PCI did not differ markedly between diabetic and non-diabetic patients in this study. The survival benefit of CABG over PCI for diabetic patients has been demonstrated only in studies with longer-term follow-ups than that used in this study.
The survival curves for diabetic patients of this study began to diverge after two years and showed a mortality rate in the PCI group almost twofold higher than that of the CABG group, although the difference was not statistically significant. A common problem of long-term comparative studies of PCI vs. CABG is that the results may become obsolete even before publication, due to the speed of technological development and advancement.
Recently, drug-eluting stents have shown very promising results on restenosis 23 , The restenosis rate following stenting may be lowered further in the future. One of the limitations of this study is that KORR is a retrospective and non-randomized study with physician-guided selection of treatment.
Although the differences measured between the two treatment groups were controlled, this statistical adjustment can be imperfect. Another important limitation is that the long-term follow-up rate is relatively low compared to previous western studies. Therefore, the two- or three-year event rate may be even less reliable. The third limitation is that the stent implantation rate was only LogConv is a utility that converts Amateur Radio log files to and from a variety of log formats.
Download Contenta Download the Free -form, Rectangular, Window, and Full Windows Mac. Windows Users' choice Cabri download free full version Cabri download free full version Most people looking for Cabri free full version downloaded: Cabri 3D.
Cabri 3D Plug-in. Cabri Geometry II. Cabri II Plus. The Company will invoice the Client for the carriage charges. The Company delivers the Products in Box Format to all countries served by the international postal services. The Company delivers the Product in Electronic Format anywhere where the full downloading of the files is possible via the network. It is up to the Client to verify the state of the packaging of the Products supplied in Box Format and to make sure that they conform to the order placed.
The date of postmark shall be proof of dispatch date. If no claim is made within the above mentioned time limit, the Products supplied in Box Format shall be deemed to conform to the order and to have been accepted by the Client.
No Product shall be exchanged before having been returned to the Company and accepted by the latter, in good condition, in the same state as dispatched by the Company. In particular, the Product must not have been unsealed. In accordance with the law, the Client is allowed seven 7 clear days, as from the date of receipt of its order, in which to cancel its order.
During that time, the Client may, at its own expense and without any penalties, return any Product or Products that it does not find suitable. The Client may then choose between either returning the Product or Products and being reimbursed for the amount paid, or exchanging the Product or Products ordered.
It is understood that the Product or Products returned at the expense of the Client must be in good condition, in the state as supplied by the Company.
Due to their duplicable nature, the software must be returned sealed or in its original packaging. In accordance with articles et sqq of the French Civil Code, the Client shall be covered by the statutory guarantee against concealed defects. The Client will then have the option of choosing between returning the Product and being reimbursed for the price, or keeping the Product and being reimbursed for part of the price.
If the Client chooses to return the Product, the cost of the return will be paid by the Company on the basis of the original method of delivery. The Client acknowledges that the Company has duly fulfilled its obligation of information. In this way, no bank details concerning the Client transit via the Company.
NB: in the event of the Client using a browser that is not compatible with the SSL system, the transaction will not be possible. The Company retains full ownership of the Products sold until full and complete payment of the price, including charges and taxes.
The mere presentation of an order to pay shall not constitute payment. The above provisions shall not debar the transfer to the Client of the risks of loss of or damage.
Should the Client fail to pay the full price, including charges and taxes, the Company shall be entitled to demand the return of the goods delivered. Any expenses incurred in such returns shall be payable by the Client. The software for which the user licence is sold on the Internet Site is guaranteed by its author, in accordance with the terms laid down in its documentation.
The Company cannot give any guarantee whatever on the software and in particular on any defects or bugs. After complete payment of the price, and except for any contradicting clauses included in the licence attached to the Product, the Client shall be granted a non transferable personal user licence for the software for an unlimited time exclusive of any right of ownership.
In accordance with the legal and statutory provisions in force, the Client shall refrain from copying the software other than as authorized by law and from performing any act liable to undermine the rights of the authors, their assignees or the Company. By express agreement, the installation of the software on a computer shall constitute unconditional acceptance of the attached user licence.
In accordance with law no. The Client has right of access to the information concerning it. Upon request, this information can be communicated to the Client and, in the event of error or of modification, can be rectified.
The Client can also prevent the communication of this information to any third party by making a request to the Company in writing. The Company disclaims all responsibility for any failure to fulfil its contractual obligations in the event of a force majeure or chance event, including, but not limited to, disasters, fires, strikes within or outside the Company, failures or breakdowns within or outside the Company, and in general any event preventing the satisfactory execution of the orders.
0コメント